Drugmakers say they will not start new trials at China military hospitals

Bristol Myers Squibb, Pfizer, Eli Lilly, AbbVie and Merck told the House Select Committee on China they will not open new trial sites in Xinjiang or at military hospitals.

By Theo Adeyemi, Regulation and biotech correspondent
. 1-minute read.
Western front of the United States Capitol building in Washington, D.C.
The western facade of the U.S. Capitol in Washington, D.C., where Congress meets. Photograph: Noclip/Wikimedia Commons (public domain)

STAT reported on Friday that five large pharmaceutical companies have told the United States House Select Committee on China that they will not open trial locations in Xinjiang or at hospitals tied to the Chinese military. The five companies are the drugmakers Bristol Myers Squibb, Pfizer, Eli Lilly, AbbVie and Merck. Each of these companies said it would not begin new clinical studies at sites connected to the People’s Liberation Army of China, according to the report. The House committee also opened investigations into the five companies last June. Those investigations were prompted by concerns about intellectual property exposure, military ties, and ethical standards at trial sites in sensitive parts of China. In its letters to the companies, the committee also said it was increasingly worried about possible security risks. STAT reported on Friday that the companies told the panel they will halt clinical trials at certain hospitals in China.

Sources: STAT

Theo AdeyemiRegulation and biotech correspondent

Theo Adeyemi covers drug regulation and the biotech industry for Clinical Observer. He writes from regulators' notices, company filings and published reporting.

Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.